Bendamustine Hydrochloride Injection – 25?mg × 2 Vials Wholesale price comparison
$2.00
Bendamustine hydrochloride is a unique bifunctional alkylating agent combining nitrogen mustard and benzimidazole structures. Supplied as sterile lyophilized powder (25?mg/vial × 2 vials), produced by Yangtze River Pharmaceutical Group. Approved in China (NMPA No.?H20213967; Code?86901749002815; Barcode?6927762520246). Strictly for laboratory research?Please consult the staff for other purposes?
描述
Bendamustine Hydrochloride Injection Specifications
| Attribute | Details |
|---|---|
| Product Name | Bendamustine Hydrochloride Injection (XianTai®) |
| Strength | 25?mg per vial (lyophilized powder) |
| Quantity | 2 vials per box |
| Dosage Form | Injectable lyophilized powder |
| CAS Number | 3543?75?7 (Bendamustine HCl) |
| Molecular Formula | C??H??Cl?N?O? · HCl (M.W. 394.7?g/mol) |
| Approval No. | China NMPA H20213967 |
| Product Code | 86901749002815 |
| Manufacturer | Yangtze River Pharmaceutical Group Co., Ltd. |
| Barcode | 6927762520246 |
| Intended Use | Research use only — Not for clinical/veterinary use |
Bendamustine Hydrochloride Injection Mechanism of Action
Bendamustine is a nitrogen mustard–benzimidazole alkylator that forms covalent DNA cross-links, disrupting DNA replication and inducing apoptosis. It is effective against slow- and fast-dividing cells and has a distinct mechanism from other alkylators. pdf.hres.ca+15en.wikipedia.org+15scbt.com+15
Research & Clinical Context
-
Approved by FDA for CLL and indolent B-cell NHL; used also with rituximab in oncology regimens.
-
Exhibits high protein binding (94–96%) and short plasma half-life (~40?min), metabolized by CYP1A2 to inactive compounds (M3, M4).
-
Clinical side effects include myelosuppression, infusion reactions, tumor lysis syndrome, infections, and dermatologic/toxic skin events.
Research Applications
Perfect for preclinical and laboratory studies in:
-
Cancer biology models: CLL, NHL, multiple myeloma
-
DNA cross-linking & replication stress assays
-
Apoptosis, cell-cycle, and toxicology studies
-
Combination therapy tests (e.g., with rituximab)
-
In vivo efficacy and PK/PD modeling
?? Research?Use Disclaimer
This product is intended strictly for laboratory research and development use only. Not intended for human, veterinary, diagnostic, or therapeutic use.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Palbociclib Capsules (Xipeilai) – 125?mg, 21 Capsules Price comparison
Palbociclib Capsules (Research Grade) in 125?mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00 -
Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison
Fulzerasib (Dupert®) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption. $1.00 -
Propranolol Hydrochloride Oral Solution 40?mg/5?mL Research & Analytical Use
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40?mg/5?mL formulation in a 40?mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00
?? For laboratory research or analytical purposes only – Not for therapeutic use. -
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00
评价
目前还没有评价